Do analysts recommend IINN or HSCS?

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 168.01%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, IINN or HSCS?

HeartSciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $289K 103.74 -$13.22M N/A N/A HeartSciences $4.32K 2,694.72 -$9.14M -$3.94 N/A

Is IINN or HSCS more profitable?

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Inspira Technologies OXY B.H.N. N/A N/A N/A HeartSciences N/A -358.60% -144.82%

Do analysts prefer HSCS or QTEX?

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 168.01%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, HSCS or QTEX?

HeartSciences has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences $4.32K 2,694.72 -$9.14M -$3.94 N/A Inspira Technologies OXY B.H.N. $289K 105.23 -$13.22M N/A N/A

Is HSCS or QTEX more profitable?

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% Inspira Technologies OXY B.H.N. N/A N/A N/A

Is HSCS or TELA more profitable?

HeartSciences has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. HeartSciences' return on equity of -358.60% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% TELA Bio -51.53% -1,320.81% -59.39%

Is BEAT or HSCS more profitable?

HeartSciences' return on equity of -358.60% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% HeartSciences N/A -358.60% -144.82%

Do analysts rate PETV or HSCS?

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 168.01%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PETV or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. HeartSciences' return on equity of -358.60% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% HeartSciences N/A -358.60% -144.82%

HeartSciences (HSCS) Competitors

$2.98 -0.05 (-1.49%)

As of 10:40 AM Eastern

Compare

HSCS vs. IINN, QTEX, TELA, BEAT, and PETV

Should you buy HeartSciences stock or one of its competitors? HeartSciences's main competitors and comparable companies include Inspira Technologies OXY B.H.N. (IINN), Inspira Technologies OXY B.H.N. (QTEX), TELA Bio (TELA), HeartBeam (BEAT), and PetVivo (PETV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

HeartSciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$289K	103.74	-$13.22M	N/A	N/A
HeartSciences	$4.32K	2,694.72	-$9.14M	-$3.94	N/A

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 168.01%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
HeartSciences	N/A	-358.60%	-144.82%

In the previous week, Inspira Technologies OXY B.H.N. and Inspira Technologies OXY B.H.N. both had 2 articles in the media. HeartSciences' average media sentiment score of 1.44 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Inspira Technologies OXY B.H.N.	Neutral
HeartSciences	Positive

Inspira Technologies OXY B.H.N. has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

HeartSciences beats Inspira Technologies OXY B.H.N. on 7 of the 12 factors compared between the two stocks.

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

HeartSciences (NASDAQ:HSCS) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

HeartSciences has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	$4.32K	2,694.72	-$9.14M	-$3.94	N/A
Inspira Technologies OXY B.H.N.	$289K	105.23	-$13.22M	N/A	N/A

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 168.01%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

HeartSciences has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.24, indicating that its share price is 324% more volatile than the broader market.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for Inspira Technologies OXY B.H.N. and 2 mentions for HeartSciences. Inspira Technologies OXY B.H.N.'s average media sentiment score of 1.89 beat HeartSciences' score of 1.44 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartSciences	Positive
Inspira Technologies OXY B.H.N.	Very Positive

Summary

Inspira Technologies OXY B.H.N. beats HeartSciences on 7 of the 13 factors compared between the two stocks.

How does HeartSciences compare to TELA Bio?

HeartSciences (NASDAQ:HSCS) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, HeartSciences and HeartSciences both had 2 articles in the media. TELA Bio's average media sentiment score of 1.89 beat HeartSciences' score of 1.44 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartSciences	Positive
TELA Bio	Very Positive

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 5.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HeartSciences has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. HeartSciences' return on equity of -358.60% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
TELA Bio	-51.53%	-1,320.81%	-59.39%

HeartSciences has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	$4.32K	2,694.72	-$9.14M	-$3.94	N/A
TELA Bio	$80.28M	0.45	-$38.83M	-$0.77	N/A

HeartSciences presently has a consensus price target of $8.00, suggesting a potential upside of 168.01%. TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 171.94%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts plainly believe TELA Bio is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

HeartSciences has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Summary

TELA Bio beats HeartSciences on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

HeartSciences has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
HeartSciences	$4.32K	2,694.72	-$9.14M	-$3.94	N/A

HeartBeam currently has a consensus target price of $4.00, indicating a potential upside of 754.70%. HeartSciences has a consensus target price of $8.00, indicating a potential upside of 168.01%. Given HeartBeam's stronger consensus rating and higher possible upside, equities analysts clearly believe HeartBeam is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HeartSciences had 1 more articles in the media than HeartBeam. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for HeartBeam. HeartBeam's average media sentiment score of 1.89 beat HeartSciences' score of 1.44 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Very Positive
HeartSciences	Positive

HeartBeam has a beta of -0.78, suggesting that its stock price is 178% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

HeartSciences' return on equity of -358.60% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
HeartSciences	N/A	-358.60%	-144.82%

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

HeartSciences beats HeartBeam on 8 of the 15 factors compared between the two stocks.

How does HeartSciences compare to PetVivo?

PetVivo (NASDAQ:PETV) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

HeartSciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. HeartSciences' return on equity of -358.60% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
HeartSciences	N/A	-358.60%	-144.82%

PetVivo has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

24.5% of PetVivo shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 10.8% of PetVivo shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 168.01%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	24.67	-$10.95M	-$0.34	N/A
HeartSciences	$4.32K	2,694.72	-$9.14M	-$3.94	N/A

In the previous week, HeartSciences had 2 more articles in the media than PetVivo. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for PetVivo. HeartSciences' average media sentiment score of 1.44 beat PetVivo's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
PetVivo	Neutral
HeartSciences	Positive

Summary

HeartSciences beats PetVivo on 12 of the 16 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.64M	$5.72B	$7.10B	$12.83B
Dividend Yield	N/A	1.75%	2.54%	11.27%
P/E Ratio	-0.76	25.70	273.04	25.49
Price / Sales	2,694.72	80.92	686.65	123.03
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	42.64	6.27	11.02	6.35
Net Income	-$9.14M	$149.94M	$3.47B	$349.46M
7 Day Performance	8.15%	-0.71%	1.03%	-0.11%
1 Month Performance	36.93%	5.85%	8.03%	4.32%
1 Year Performance	-12.46%	5.75%	23.72%	14.79%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	2.8029 of 5 stars	$2.99 -1.5%	$8.00 +168.0%	-11.1%	$11.64M	$4.32K	N/A	10	Positive News Short Interest Decrease
IINN Inspira Technologies OXY B.H.N.	0.0164 of 5 stars	$0.90 -4.5%	N/A	-27.5%	$32.26M	$289K	N/A	20	News Coverage High Trading Volume
QTEX Inspira Technologies OXY B.H.N.	0.5509 of 5 stars	$1.12 +24.8%	N/A	N/A	$32.26M	$290K	N/A	20	News Coverage Positive News Gap Up High Trading Volume
TELA TELA Bio	3.7354 of 5 stars	$0.65 +0.6%	$2.20 +240.0%	-60.7%	$28.87M	$80.28M	N/A	120	Positive News Gap Down
BEAT HeartBeam	2.4524 of 5 stars	$0.48 +0.6%	$4.00 +728.5%	-65.5%	$27.05M	N/A	N/A	1,700	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. IINN, QTEX, TELA, BEAT, and PETV

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Summary

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Summary

How does HeartSciences compare to TELA Bio?

Summary

How does HeartSciences compare to HeartBeam?

Summary

How does HeartSciences compare to PetVivo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. IINN, QTEX, TELA, BEAT, and PETV

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Which has better earnings and valuation, IINN or HSCS?

Do analysts recommend IINN or HSCS?

Is IINN or HSCS more profitable?

Does the media refer more to IINN or HSCS?

Which has more risk & volatility, IINN or HSCS?

Do institutionals & insiders have more ownership in IINN or HSCS?

Summary

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Which has better earnings & valuation, HSCS or QTEX?

Do analysts prefer HSCS or QTEX?

Is HSCS or QTEX more profitable?

Which has more volatility & risk, HSCS or QTEX?

Do institutionals and insiders have more ownership in HSCS or QTEX?

Does the media refer more to HSCS or QTEX?

Summary

How does HeartSciences compare to TELA Bio?

Does the media prefer HSCS or TELA?

Do insiders & institutionals believe in HSCS or TELA?

Is HSCS or TELA more profitable?

Which has preferable earnings & valuation, HSCS or TELA?

Do analysts prefer HSCS or TELA?

Which has more volatility and risk, HSCS or TELA?

Summary

How does HeartSciences compare to HeartBeam?

Which has preferable valuation and earnings, BEAT or HSCS?

Do analysts prefer BEAT or HSCS?

Does the media favor BEAT or HSCS?

Which has more volatility & risk, BEAT or HSCS?

Is BEAT or HSCS more profitable?

Do institutionals & insiders have more ownership in BEAT or HSCS?

Summary

How does HeartSciences compare to PetVivo?

Is PETV or HSCS more profitable?

Which has more risk & volatility, PETV or HSCS?

Do institutionals and insiders have more ownership in PETV or HSCS?

Do analysts rate PETV or HSCS?

Which has stronger earnings and valuation, PETV or HSCS?

Does the media favor PETV or HSCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools